Summarized by Masters of Longevity from Longevity Technology.
ProMIS' leadership move and commercial planning for an Alzheimer’s therapy — a news article about corporate hiring and market-readiness strategy.
Key Takeaways
- ProMIS hired an experienced neuroscience executive to lead commercial preparation for PMN310 and related strategies.
- PMN310 is a humanized monoclonal antibody aiming to selectively target toxic amyloid-beta oligomers while avoiding monomers and plaques.
- Unblinded 12-month topline results from the PRECISE-AD Phase 1b study are expected in the first quarter of 2027.
